Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023Business Wire • 06/17/23
Bristol Myers Squibb sues federal government over Medicare drug negotiations: reportMarket Watch • 06/16/23
U.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS® (mavacamten) LabelBusiness Wire • 06/16/23
Goldman Sachs Says Traders Should Use Options to Load Up on These 5 ‘Strong Buy' Blue Chips24/7 Wall Street • 06/15/23
Bristol-Myers Squibb Company (BMY) Presents at Goldman Sachs 44th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 06/13/23
Bristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, MassachusettsBusiness Wire • 06/08/23
Bristol-Myers Squibb Company (BMY) Presents at Jefferies Healthcare Conference (Transcript)Seeking Alpha • 06/08/23
Bristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023Business Wire • 06/08/23
Bristol-Myers Squibb Company (BMY) Presents at 2023 Virtual ASCO Investor Event Conference (Transcript)Seeking Alpha • 06/06/23
MEDiC Life Sciences Announces Collaboration with Bristol Myers Squibb on Tumor Target DiscoveryBusiness Wire • 06/05/23
Four-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung CancerBusiness Wire • 06/04/23